Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma.
Braz J Otorhinolaryngol
; 88(4): 523-528, 2022.
Article
en En
| MEDLINE
| ID: mdl-32972866
ABSTRACT
INTRODUCTION:
Papillary thyroid carcinoma is the most frequent endocrine neoplasia and its incidence has tripled over the past 35â¯years. Although papillary thyroid carcinoma carries a good prognosis, 10%-30% of patients still develop recurrence and metastasis. Some clinical and genetic features are associated with worse prognosis. The most frequent mutation is the BRAF p.V600E, which has been associated with many clinical features of poor prognosis. However, many studies have produced controversial results without any association between BRAF mutation and clinicopathological features of poor prognosis.OBJECTIVE:
Since the prognostic value of BRAF mutations remains controversial, this study aims to investigate the importance of this mutation in therapeutic decisions for papillary thyroid carcinoma.METHODS:
Therefore, we evaluated whether the presence of BRAF mutation is associated with features of poor prognosis in 85 patients with papillary thyroid carcinoma older than 45â¯years treated at A.C. Camargo Cancer Center, from 1980 to 2007. BRAF mutation was evaluated by pyrosequencing. Statistical analysis was performed using SPSS.RESULTS:
The mean age of patients was 54 years (range 45â¯-â¯77 years), 73 were women (85.8%) and 12 were men (14.2%). Among them, 39 cases (45.9%) presented extrathyroidal extension and 11 cases had recurrent disease. BRAF mutation was detected in 57 (67%) patients. No significant association was observed between BRAF mutation and gender (p â¯=â¯0.743), age (p â¯=â¯0.236), N-stage (p â¯=â¯0.423), vascular and perineural infiltration (p â¯=â¯0.085 or multifocality (p â¯=â¯1.0). Although not statistically significant, the majority of patients with recurrent disease were BRAF positive (9 out of 11) (p â¯=â¯0.325). Patients affected by BRAF mutation are associated with tumors larger than 1â¯cm (p â¯=â¯0.034) and with extrathyroidal extension (p â¯=â¯0.033).CONCLUSION:
Although BRAF testing is widely available, there are no consistent data to support improvement in outcomes from incorporating it into therapeutic decision for thyroid cancer.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias de la Tiroides
/
Proteínas Proto-Oncogénicas B-raf
/
Cáncer Papilar Tiroideo
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Braz J Otorhinolaryngol
Asunto de la revista:
OTORRINOLARINGOLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Brasil